Murcia, Spain — May 2025
Probelte Pharma has announced that the full protocol for the PROACAROS phase III clinical trial, designed to evaluate the efficacy and safety of Beltavac® subcutaneous immunotherapy in patients with house dust mite allergic rhinitis, has been published in the prestigious scientific journal TRIALS.
By publishing this article, Probelte Pharma has become the first and only company in the allergen immunotherapy industry to publicly and transparently share the detailed methodology of a clinical trial of this kind. This milestone underscores the company’s commitment to scientific excellence, regulatory innovation, and further developing precision treatments for allergic patients.
This article has brought key added value for the scientific and regulatory defence of the project by aligning with the guidelines of the European Medicines Agency (EMA) and the European Academy of Allergy and Clinical Immunology (EAACI). Furthermore, the protocol included technological tools specifically designed to support digital patient monitoring and the real-time assessment of clinical outcomes, thus building a more agile, robust and patient-centred research model.
The publication of the PROACAROS trial cemented Probelte Pharma’s role as a leading source of high-quality scientific evidence and underlined its strong commitment to the future of allergen immunotherapy.
View the full article here: